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Abstract 
 
ABSTRACT 
Osteonecrosis of the jaw (ONJ) is a serious complication of oncological patients after or during 
drug therapy, whose manifestations range from asymptomatic to aspects requiring extensive 
operative treatment and adversely affecting patient’s qualify of life. Taking in account that the 
lack of supplementation vitamin D causes hypovitaminosis, increasing bone renewal, losing 
bone mass, and in severe cases determing osteomalacia (one of the risk factors for ONJ) and 
that the probability of developing ONJ increases significantly during the first 3 years of 
treatment, the  main objective of the present study is to assess whether the implementation of 
high-dose vitamin D in oncologic patients treated with zoledronic acid plus the well-known 
primary prevention protocols for elimination of potential risk factors could effectively reduce 
the risk of ONJ. 
Given the simplicity, safety and low costs of vitamin D supplementation, the finding of a real 
protective effect on the development of ONJ may have important implications in clinical 
practice, making safer the administration of zoledronic acid. 
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Summary 
 
SUMMARY 
 
 
Background. Osteonecrosis of the jaws (ONJ) is a potentially severe adverse effect of oral 
disease of some medications such as bisphosphonates, antiresorptive and antigenic drugs. ONJ 
pathogenesis is yet unclear and some risk factors have been recognized. Among these, vitamin 
D deficiency has been hypothesized as a potential risk factors for ONJ development. 
Objectives. The primary objective of the present study is to estimate the incidence of ONJ in a 
group of oncologic patients treated with zoledronic acid receiving high-dose vitamin D 
supplementation after application of well-known prevention strategies for elimination of 
potential risk factors and risk reduction of ONJ. 
Methods. Between January 2014 and December 2015, a total of 82 oncologic patients were 
collected.  Patients have been allocated into two groups above mentioned. Group T patients 
received vitamin D implementation during the treatment with zoledronic acid. Group C patients 
did not received vitamin D implementation during the treatment with zoledronic acid.  
Results.  In the group T the median duration of antiresorptive therapy was of 14,03 (SD=±2,77). 
In the group C the median period of BPs assumption was 17,78 months (SD=±3,00). To date, no 
ONJ cases have been observed in group T; on the contrary  6 (11,1%) patients developed ONJ in 
group C. 
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Conclusions. The findings of this study support the value that primary preventive measures plus 
the implementation of high-dose vitamin D could reduce the risk of occurrence of ONJ in a high-
risk oncological population. However, further investigation to assess the real benefit of high 
dose vitamin D supplementation are needed. 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 1 
 
 
 
 
 
Background, Rationale and Objectives 
 
 
 
 
 
 
BACKGROUND 
 
 
 
Osteonecrosis of the jaw (ONJ) is a severe adverse drug reaction, that has been defined as a 
progressive destruction and death of bone that affects the mandible and/or maxilla of patients 
exposed to the treatment particularly with nitrogen-containing bisphosphonates (BPs), in the 
absence of a previous radiation treatment [1]. 
Since 2003, such lesion have been initially termed bisphosphonate-related osteonecrosis of the 
jaw (BRONJ) as it usually followed the administration of different types of bisphosphonates 
(BPs) [2, 3].  
The first definition of ONJ was introduced by the American Association of Oral and Maxillofacial 
Surgery (AAOMS) [10] and comprised the following criteria: 
 
 Current or previous treatment with BPs;  
 Exposed bone in the maxillofacial region that has persisted for more than 8 weeks; 
 No history of radiation therapy to the jaw.  
 
This definition, which relies heavily upon the presence of clinically evident necrotic bone 
exposed through the oral mucosa or facial skin, has been adopted by the vast majority of 
clinical and epidemiological studies, and commonly used in clinical trials for case adjudication. 
However, several independent reports have recently highlighted that ONJ does not always 
present with oral mucosa fenestration and necrotic bone exposure; indeed, the non-exposed 
variant of jaw osteonecrosis, initially reported in 2008, has been characterized by other clinical 
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features of the jaw, in the absence of frank bone exposure [4-6]. Of note, diagnosis of non-
exposed ONJ is based on exclusion of common jawbone diseases, such as odontogenic 
infections and other bone disorders known to cause similar manifestations. 
In 2012 the SICMF (Italian Society of Maxillofacial Surgery) and the SIPMO (Italian Society of 
Oral Pathology and Medicine) proposed a new definition [1]: “Bisphosphonate related 
osteonecrosis of the jaw (BRONJ) is an adverse drug reaction described as the progressive 
destruction and death of bone that affects the mandible or maxilla of patients exposed to the 
treatment with nitrogen-containing bisphosphonates, in the absence of a previous radiation 
treatment. 
In last years, the term Medication Related Osteonecrosis of Jaw (MRONJ) has been recently 
introduced in medical literature, in consideration of the fact that ONJ also occurs for other class 
of drugs such as denosumab, a bone resorption inhibitor of the receptor activator of nuclear 
factor-kappa B ligand (RANKL) antibody family, anti-angiogenesis inhibitor (e.g. bevacizumab, 
sunitinib, everolimus), [7]. 
Bisphosphonates (BPs) are antiresorptive agents widely prescribed in the treatment of skeletal 
diseases. BPs inhibit bone resorption mainly conditioning osteoclast activity and they are 
effective in the prevention of bone complications in patients with multiple myeloma  and  bone  
metastases from solid tumors. While the potential for bisphosphonates to improve cancer-
specific survival remains controversial, these medications had a significant positive effect on 
the quality of life for patients with advanced cancer involving the skeleton. 
Denosumab, a RANK ligand inhibitor is an antiresorptive medication that inhibits osteoclast 
function, decreases bone resorption, and increases bone density. Denosumab therapy is not 
indicated for the treatment of multiple myeloma. Interestingly, in contrast to bisphosphonates, 
denosumab do not bind to bone and its effects on bone remodeling are mostly diminished 
within 6 months of treatment cessation. 
However, evidence shows that bisphosphonates reduce skeletal morbidity in multiple myeloma 
and solid tumors affecting bone by 30–50% [8, 9]. Otherwise, recent studies have shown that 
denosumab can be even more effective than BPs in reducing the incidence and delaying the 
time to SREs [10]. 
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1.1.1   Epidemiology 
 
 
The real epidemiology of ONJ remains unclear due to inconsistency and limitations of available 
studies, including a lack of a specific ICD code, under-reporting in surveillance drug systems, a 
recent introduction of preventive measures, case adjudication restricted to exposed ONJ, short-
term observation and a lack of cumulative long-term incidence rates.  
In patients with cancer exposed to zoledronate, the cumulative incidence of ONJ ranges from  
0.7 to 6.7%. The risk of ONJ in patients with cancer exposed to zoledronate ranges from 50 to 
100 times higher than in patients with cancer treated with placebo [7].  
 
1.1.2   Pathophysiology 
 
 
Even if ONJ pathogenesis is not defined, there are several hypothesis that could explain its main 
localization to the jaws: inflammation or infection, chronic microtrauma, altered bone 
remodeling or over suppression of bone resorption, angiogenesis inhibition, soft tissue 
medication toxicity, terminal vascularization of the mandible, suppression of immunity [11, 12]. 
 
A. Inhibition of osteoclastic bone resorption and remodeling 
Bisphosphonates and denosumab inhibit osteoclast differentiation and function, and increase 
apoptosis, all leading to decreased bone resorption and remodeling [13, 14].  
Nitrogen-containing bisphosphonates (pamidronate, alendronate, risedronate, incadronate, 
zoledronate) target the intracellular enzyme farnesyl diphosphonate synthase, inhibiting the 
mevalonate pathway, resulting in disruption of post-translational intracellular signaling proteins 
such as Ras). This would alter cytoskeletal organization and cell motility, resulting in osteoclast 
apoptosis. Furthermore, bisphosphonates disrupt normal bone homeostasis, resulting in 
impaired healing, especially in bone exposed to constant trauma, which may determine 
necrosis. In contrast, the effect of denosumab as an antibody is temporary. It has been shown 
that remodelling of the jaw bone resumes when denosumab is discontinued. 
Based on the action mechanisms of these medications, it has been reported that bone turnover 
plays an important role in osteonecrosis. Indeed, the reason why osteonecrosis occurs in the 
jaw rather than in other long bones is explained by the strong suppression of the bone turnover 
in jaw bone after experimental bisphosphonate administration in preclinical study and more 
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rapid cortical bone turnover in the human alveolar bone [15]. The central role of bone 
remodeling inhibition is further corroborated by a similar incidence of ONJ observed with other 
antiresorptive medications such as denosumab [7]. 
 
 
B. Inflammation/Infection 
Both systemic and local oral risk factors have been implicated in ONJ pathogenesis, where 
several human studies have implicated dental disease or bacterial infection. Although tooth 
extraction has been performed in most of the initial reported cases of ONJ, these teeth 
commonly had existing periodontal or periapical disease [9]. However, it is not clearly defined 
whether osteonecrosis occurs first and then the necrotic lesion becomes to be infected, or 
infected lesion becomes to undergo osteonecrosis. Since the active resorption does not occur 
in bisphosphonate-containing bone, the infected tissue is not readily removed completely and 
can easily progress to chronic osteomyelitis.  
Inflammation or infection has long been considered an important component of ONJ. Early 
studies identified bacteria, especially Actinomyces species, in biopsied specimens of necrotic 
bone removed in patients with ONJ [16]. 
 
C. Inhibition of Angiogenesis 
Angiogenesis is a process that involves growth, migration and differentiation of endothelial cells 
to form new blood vessels. Angiogenesis favorably influences tumor growth and also influences 
tumor invasion of vessels, resulting in tumor metastasis. Angiogenesis requires binding of 
signaling molecules such as vascular endothelial growth factor (VEGF) to receptors on the 
endothelial cells. This signaling promotes new blood vessel growth. 
Bisphosphonates have an anti-angiogenic effect [17]. Osteonecrosis is classically considered an 
interruption in vascular supply or avascular necrosis, and therefore, it is not surprising that 
inhibition of angiogenesis is a leading hypothesis in ONJ pathophysiology [18]. In vitro 
experiments consistently demonstrate a reduction in angiogenesis in response to zoledronic 
acid. Studies in cancer patients treated with zoledronic acid support these data with decreased 
circulating VEGF levels [19]. Moreover, there is a growing body of literature linking 
osteonecrosis of the jaw and other bones in patients receiving novel antiangiogenic drugs 
(tyrosine kinase inhibitors and monoclonal antibody targeting VEGF) [17].  
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D. Other Hypotheses 
Soft tissue toxicity 
Although bisphosphonates primarily act on osteoclasts, they also have direct toxicity towards 
soft tissues such as oral epithelial cells. BPs suppress the proliferation and transportation of oral 
keratinocytes [18, 20], which can increase the chances of latent bone exposure and subsequent 
infection. However, after reaching the bloodstream, bisphosphonates are mostly excreted 
through the kidneys after a few hours, and the concentration of bisphosphonates in tissues 
other than the bone are reported to be quite low.  
 
Immune-related, or hair-line fracture-related theories 
Bisphosphonates control the activity of various cells that are involved in the immune response 
[21]. The risk of osteonecrosis after tooth extraction becomes significantly higher if steroids  or 
chemotherapeutic agents, which may influence the innate/acquired immune system, are given 
during bisphosphonate administration [22-24]. Bone tissue is constantly undergoing the 
repetitive micro-fractures and healing process throughout the life, and such micro-trauma is 
slowly accumulated by age [25]. Micro-fractures caused by normal mastication are slowly ac-
cumulated due to the suppressive effect of bisphosphonates on osteoclasts or osteoblasts, 
resulting in latent osteonecrosis lesions [26]. Bacterial invasion of these lesions may cause 
progression to a deeper infection [27]. The results of various animal studies would support 
above-mentioned hypotheses. However, there are also many contradictory evidences that do 
not support such theories. Therefore, ONJ is probably caused by multiple, combined factors 
that cannot be explained by a single pathophysiologic mechanism. 
 
 
 
 
1.1.3   Clinical manifestation 
 
 
Exposed ONJ is characterized by the presence of clinically evident necrotic bone, which is 
exposed through the oral mucosa or facial skin, tending to affect the mandible more frequently 
than the maxilla [28]. Common associated manifestations include soft tissue swelling and 
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erythema, pus discharge, fistula/sinus tracts, tooth loss, jaw deformity, pain and sensory 
disturbances. The dimension of exposed bone in ONJ can vary from a few millimeters to several  
centimeters. Of note, little is known regarding the true extension of necrotic bone surrounding 
the superficial exposed areas, as very few studies have reported data from radiographs, 
computed tomography (CT) or MRI scans [29]. It seems that the vast majority of patients 
present with localized bone disease, which often is painful and infected. 
Non-exposed clinical variant of ONJ include otherwise unexplained jawbone pain, fistula/sinus 
tract, swelling, loose teeth and pathological fractures [4, 6, 30, 31]. Notably, these clinical signs 
and symptoms are not correlated to dental, periodontal or other possible jawbone disorders 
causes and indeed the diagnosis of non-exposed ONJ is one of exclusion. 
 
 
 
1.1.4   Risk factors 
 
 
Many risk factors are well recognized and are usually categorized in three groups:  
 Drug-related: type, duration and dosage, administration route. 
 Systemic: age, diabetes, vitamin D deficiency, suppressed bone turnover markers, 
genetic factors, concomitant steroids. 
 Local: intraoral surgery (e.g. tooth extraction), local anatomical factors, concomitant 
oral disease (e.g. periodontitis). 
 
A. Drug-related risk factor 
Type of drugs 
Administered drugs: in hematological and oncological patients, zoledronic acid (administered to 
the majority of ONJ patients but also the drug most commonly used, at least after 2002) seems 
to result in a statistically higher risk of ONJ. Among cancer patients exposed to zoledronate, the 
cumulative incidence of ONJ is in the low single digits (range = 0.7% - 6.7%) [32]. When limited 
to studies with Level 1 evidence (i.e. systematic reviews or RCTs), the risk of ONJ in subjects 
exposed to zoledronate approximates 1% (100 cases per 10,000 patients) [33]. The risk of ONJ 
among cancer patients exposed to zoledronate ranges between 50-100 times higher than 
cancer patients treated with placebo [7].  
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Duration of bisphosphonate use 
On average, ONJ patients were treated for longer periods than those without ONJ. The duration 
of intravenous treatment with BPs is generally correlated with the total dose of drug 
administered, given the type of monthly administration, continuous and indefinite in time, 
recommended by major guidelines, at least until 2007 [34, 35]. Regardless of indications for 
therapy, the duration of BP or antiresorptive therapy continues to be a risk factor for 
developing ONJ. Among cancer patients exposed to zoledronate or denosumab, the incidence 
of developing ONJ was, respectively, 0.6 and 0.5% at 1 year, 0.9 and 1.1% at 2 years, and 1.3 
and 1.1% at 3 years with the risk for ONJ among denosumab-exposed subjects plateauing 
between years 2 and 3 [36].  In a study by Saad, et al, the investigators combined three-blinded 
phase three trials and found similar results, including a plateau after 2-years for patients 
exposed to denosumab [23]. Among cancer patients exposed to zoledronate or denosumab 
(n=5723), the incidence of developing ONJ was, respectively, 0.5 and 0.8% at 1 year, 1.0 and 
1.8% at 2 years, and 1.3 and 1.8% at 3 years [7]. 
Regarding total dose of administered (cumulative doses), available data indicate a higher risk of 
developing ONJ with an increase in total BPs dose, which is intravenously administered monthly 
to cancer and hematological patients, both for zoledronate and pamidronato [9]. 
Administration route 
There is a higher risk for intravenous injection of BPs but this factor may be closely related to 
the greater drug bioavailability and their prevalent use in cancer patients (at significantly higher 
total doses and durations) [9]. 
 
B. Systemic risk factor 
Old age  
ONJ shows an increasing trend in patients of old age. It has been reported that the prevalence 
increases in patients older than 65 years of age, and a similar trend has been reported in local 
studies, with the highest prevalence seen in patients 75 to 79 years of age [23].  
Diabetes 
The risk of ONJ is increased in diabetes patients [23]. This is thought to be due to decreased 
bone quality following ischemia of capillaries, decreased function of vascular endothelial cells, 
and increased apoptosis of osteoblasts and osteocytes caused by diabetes, in addition to 
decreased function of immune cells and increased inflammation seen in diabetes. 
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Vitamin D deficiency 
When a vitamin D deficiency is present, calcium absorption decreases by 15% (phosphorous 
absorption by 60%), reducing serum ionized calcium. This decrease is detected by parathyroid 
gland calcium sensors, which respond with an increase in parathyroid hormone (PTH) whose 
function is to maintain serum calcium levels, acting on the liver and on bone where it stimulates 
bone resorption. 
When the calcium supply to the organism is inadequate, the vitamin D hormonally active 
metabolite (1,25 (OH)2D) helps maintain calcium homeostasis, acting on vitamin D receptors 
(VDR) of the osteoblasts in which receptor activator of nuclear factor kappa-B ligand (RANKL) 
formation is induced in a similar way as with PTH, so producing bone resorption for calcium 
homeostasis. When the major circulating vitamin D metabolite (25(OH)D) levels are very 
reduced a failure to produce correct calcium absorption in the intestine occurs, with insufficient 
substrate for converting 1,25(OH)2D, even when PTH levels are high. 
The optimal level of vitamin D has recently been described as follows: sufficient vitamin D 
concentration so that serum PTH levels are neither elevated nor decreased when vitamin D 
supplements are taken [37]. 
It has been indicated that hypovitaminosis D changes bone metabolism, increases bone 
renewal, losing bone mass, and in severe cases can lead to osteomalacia. Severe 
hypovitaminosis D (i.e. osteomalacia)  is characterized by an impairment of bone mineralization 
and is commonly caused by a decrease of the serum calcium-phosphate product, which has 
multiple causes.  
Bedogni et al. evaluated histomorphometric parameters in bone samples taken from patients 
treated with bisphosphonates. 77% of patients with ONJ suffered of osteomalacia compared 
with 5% of those who did not have ONJ. Given that osteomalacia was found almost exclusively 
among patients with osteonecrosis, it can be said that osteomalacia could represents a risk 
factor for osteonecrosis pathogenesis [38]. 
Further studies indicated that vitamin D insufficiency was related to ONJ [39, 40]. Hokugo et al. 
developed a vitamin D-deficient rat model and tested combinations of risk factors for ONJ. They 
suggested that the group with intravenous zoledronic acid and vitamin D deficiency showed a 
higher rate of ONJ. Mastaglia et al. indicated that a vitamin D insufficiency plus BPs therapy 
group showed significantly lower values of bone mass and bone volume. 
In addition, the results of recent study indicated that vitamin D affects also histopathological 
parameters, such as the numbers of osteoblasts and osteoclasts, as well as histological and 
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macroscopic osteonecrosis, especially in the group administered vitamin D after tooth 
extraction, and it can be concluded that vitamin D diminished the suppressive effects of BPs 
[41]. 
Genetic factors 
Individual genetic susceptibility to ONJ development has been investigated in a small number of 
genome-wide association and candidate gene studies. The largest study performed so far (n = 
94 ONJ cases) suggests that MHC class II polymorphisms may represent genetic risk factors 
related to the development of ONJ [9]. 
Steroid therapy 
The risk of ONJ increases in patients on steroids [23, 24]. The reason for this is thought to be 
due to decreased immune cells and delayed wound healing related to steroid use, which in turn 
exacerbates oral inflammation and increases the risk of ONJ. However, the difference in 
incidence of ONJ caused by the use of medications is mostly based on the results of 
retrospective studies, therefore, further prospective studies are needed. 
 
 
C. Local risk factors  
Dentoalveolar surgery 
In the international literature, dental extraction is considered one of the most significant risk 
factors associated with ONJ in cancer patients taking antiresorptive drugs. Several studies 
report that among patients with ONJ, tooth extraction is a common predisposing event ranging 
from 52 to 61% of patients reporting tooth extraction as the precipitating event [7, 23]. 
Interestingly, some patients develop ONJ without surgical dental procedures or other risk 
factors during treatment with bisphosphonates or denosumab. Therefore, the true incidence, 
etiology, and risk factors that contribute to ONJ pathogenesis are unknown in cancer patients 
[42]. 
The risk of developing ONJ among patients who have been exposed to antiresorptive 
medications for other dentoalveolar procedures such as dental implant placement and 
endodontic or periodontal procedures is unknown. Absent data, the committee considers the 
risk for ONJ after dental implant placement and endodontic or periodontal procedures that 
require exposure and manipulation of bone to comparable to the risk associated with tooth 
extraction. 
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Local anatomical factors  
Protruded bone surfaces are covered by relatively thin mucous membranes, so that continuous 
irritation by dentures, etc. can lead to exposure of the surface and contribute to the 
pathogenesis of ONJ. Other anatomical landmarks such as a mandibular torus, the mylohyoid 
ridge, or a palatine torus can be vulnerable anatomic structures and act as local risk factors. 
Concomitant oral disease 
Dental and periodontal infection significantly increases the risk of ONJ in cancer patients 
exposed to antiresorptive therapy. Indeed, periodontal disease was diagnosed in 84% of cases 
in a large sample of patients with ONJ. However, periodontal disease is commonly observed in 
the general population in individuals >40 years of age, which may represent a confounding 
factor in assessing epidemiological association. Also, early clinical stages of ONJ are known to 
include non-exposed alveolar bone necrosis that can mimic clinical and radiological 
manifestations [9]. 
 
 
 
1.2  RATIONALE 
 
 
Medication-related osteonecrosis of the jaw is a well-documented adverse event of therapy 
with specific drugs (e.g. BPs, denosumab, bevacizumab, sunitinib).   
The pathogenesis is multifactorial and several risk factors are recognized.  As described in 1.1.4 
paragraph, the deficit of vitamin D and especially severe hypovitaminosis D modify bone 
metabolism with bone impairment and have been detected in ONJ lesions [38-41]. 
Up to date, in literature there are not prospective studies evaluating the effect of vitamin D 
implementation in oncologic patients before ONJ development. About this, arguing in term of 
prevention, we supposed that the well-known strategy for primary prevention of zoledronic 
acid -related ONJ and the high-dose vitamin D implementation together could have a greater 
effect in ONJ development.  
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1.3  OBJECTIVES 
 
 
The  primary  objective of the present study is to estimate the incidence of ONJ in a group of 
oncologic patients treated with zoledronic acid receiving high-dose vitamin D supplementation 
after application of well-known prevention strategies for elimination of potential local risk 
factors and risk reduction of ONJ. 
Moreover, secondary aims include the evaluation of changes in bone metabolism during 
treatment with vitamin D and of periodontal oral health by plaque index, bleeding on probing 
(BoP), clinical attachment level (CAL) and tooth loss (TL). 
  
CHAPTER 2 
 
 
 
 
 
Materials/Patients and Methods 
 
 
 
 
 
 2.1 Study design 
 
 
Prospective cohort study: 
 Group T: naïve patients in primary prevention for ONJ receiving zoledronic acid and high 
dose vitamin D supplementation. 
 Group C:  naïve patients in primary prevention for ONJ receiving zoledronic acid without 
high dose vitamin D supplementation. 
 
 
2.2  Patients 
 
 
Between January 2014 and December 2015, a total of 82 oncologic naïve patients were 
collected with the following inclusion criteria:  
 age ≥ 18; 
 diagnosis of cancer (in which antiresorptive therapy is required); 
 signed informed consent. 
Exclusion criteria were: 
 previously or currently treatment with bisphosphonates, denosumab and/or other 
antiangiogenic drugs (e.g. bevacizumab); 
 previous diagnosis of ONJ; 
 history of head-neck radiotherapy. 
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The ethics committee approved for the study (Internal Ethical Committee of the University 
Hospital A.U.O.P “P. Giaccone” of Palermo -Internal registry: 9/2015) and the patient’s consent 
to participate was obtained where specifically required. The study was performed in 
accordance with the ethical standards of the Declaration of Helsinki. 
 
 
 
2.3  Data collection and variables 
 
 
Medical notes of patients were collected. Following data (demographical, pathological 
anamnesis, local clinical and radiological indexes) were registered by clinical experts and 
entered into a pre-defined electronic database. 
Demographical and Medical measurements: 1) age, 2) sex, 3) bone disorders and co-
morbidities. During follow up 4) zoledronic acid assumption, 5) zoledronic acid duration and 6) 
local risk factors for ONJ were also registered; in case of ONJ development 7) ONJ site, 8) 
clinical manifestation of ONJ (bone exposure or non exposure), 9) abscess, 10) pain, 11) ONJ 
stadiation (according to SICMF – SIPMO). 
Hematologic measurements: D25 (OH) D, Ca, P,  PTH, nitrogen and creatinine. 
Periodontal measurement: plaque index, bleeding on probing (BoP), clinical attachment level 
(CAL) and tooth loss (TL). 
Radiologic measurements: baseline dental panoramic x-ray to identify any relevant pathology 
and to provide a baseline radiograph of the jaws and teeth.  
All data of two groups were shown respectively in Table 1-2. 
 
 
2.4  Description of clinical protocol 
 
 
After having signed an informed consent, patients were included into primary 
prevention strategies for elimination of potential local risk factors and risk reduction of ONJ. 
Then patients have been submitted to a preliminary oral evaluation, clinically and radiologically 
in order to evaluate the state of hard and soft tissues.  
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In case of gingivitis or periodontal disease, patients were underwent to causal therapy for 
eliminating status of inflammation and infection. 
In case of invasive dental treatments (i.e. tooth extractions), the administration of 
antiresorptive therapy for both groups have been postponed till a complete recovery of 
biological tissues. 
All patients underwent to a blood sampling for the assessment of serum levels of D 25 (OH) D, 
Ca, P, PTH, nitrogen and creatinine. 
Patients have been allocated into two groups above mentioned. Group T patients received 
vitamin D implementation during the treatment with zoledronic acid. Group C patients did not 
receive vitamin D implementation during the treatment with zoledronic acid.  
Oral vitamin D administration was scheduled as follows:  
 loading dose of 100,000 IU/day for the first 3 days; 
 maintenance dose of 100,000 IU of vitamin D once monthly for the duration of the 
study. 
Every 4 months after the enrolment and for the entire duration of the observation period the 
patients underwent a dental examination and re-evaluation of the dental-periodontal status to 
exclude the presence of ONJ and to intercept any inflammatory processes / infectious in order 
to establish early prevention therapies. 
 
 
 
2.5  Statistical analysis 
 
 
Incidence rates per 1,000 person-months were calculated for both experimental and control 
groups. 
Survival rates were calculated by the Kaplan-Meier method at 3, 6, 12, 18 and 24 months from 
the start of  bisphosphonates therapy. The log-rank test was used to compare survival rates 
between experimental and control groups. A 2-sided   value of 0.05 or less was considered to 
assess statistical significance. All statistical analyses were carried out using Stata/SE 14.1 
(StataCorp LP, Texas US).  
  
CHAPTER 3 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
82 naïve oncological patients were collected from January 2014 and December 2015. The 
patients ranged in age from 32 to 81 years. The 29 patients of group T had a mean age of 64.78 
years (range 48-81) and group C consisted of 53 patients who were 59,62 years old (range 32- 
81). Data of each patients were registered and patients have followed up for a mean time of 
14,03 months group T and 17,78 group C. All data of two groups were summarized respectively 
in Table 1-2.  
All patients received zoledronic acid for malignant diseases. Breast and prostate cancer were 
the two most frequent cancer of the two group (T and C), 50,0% and 28,0% respectively. Other 
indications were multiple myeloma and solid tumors (lung, colon, liver). 
In particular, in the group T the median duration of zoledronic acid therapy was of 14,03 
months (SD=±2,77). Vitamin D supplementation started with BP administration according to our 
protocol as reported in paragraph 2.4. In the group C the median period of zoledronic acid 
assumption was 17,78 months (SD=±3,00).  
During treatment with zoledronic acid, 5 patients received other drug-related ONJ (Tab. 1 and 
2). In particular,  among group T patients, only 1 (3.1%) patient received bevacizumab from 
August 2015 to January 2016; on the other hand in group C 4 (7,4%) patients have been taking 
bevacizumab since zoledronic therapy started. 
Eight patients were in treatment with systemic steroids, 1 (3.4%) and 5 (9.4%) in group T and C 
respectively. On one hand, 3 patients have been taking steroid for months: group T patient for 
19 months, group C  patients (i.e. ID 14 and 33) for 16 and 12 months respectively; on the other 
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hand, 3 group C patients (i.e. ID 5, 6 and 41) received steroid for 15, 17 and 19 months 
respectively.  
Every 4 months, a dental-periodontal evaluation has carried  out to intercept any inflammatory 
processes / infectious and to apply secondary prevention protocol of ONJ. Local data of each 
patient was collected and registered in a periodontal chart, evaluating plaque index, bleeding 
on probing (BoP), clinical attachment level (CAL) and tooth loss (TL). No statistically significant 
differences were observed until now. Patients underwent to oral hygiene session every and not 
more than 6 months after clinical evaluation. Chlorexidine 0,2% mouthwashes 30 ml swished 
up to 60 seconds, 3 times/ daily for 7 days were prescribed. 
In both groups, no dental extractions were performed during our study.  
After a 14,03 month mean period of observation, no ONJ cases have been observed in group T; 
on the contrary, 6 (11,3%) patients developed ONJ in group C during 17,78 months. The 
mandible was affected in the totally of cases. The most frequent sign at presentation was bone 
exposure (83.3%), generally asymptomatic.  
ONJ was defined and classified according to SICMF – SIPMO classification [1], as follows: 4 
patients with stage 1 (66.7%) and 2 patients with stage 2 (33.3%). All data were shown in Tab. 
3. 
Overall in the time-span Jan.2014-Dec.2016, 408 person-months were included in the 
experimental group (N=32 people) and no cases of ONJ were diagnosed. Conversely, 960 
person-months were included in the control group (N=54 people) and 6 new cases of ONJ were 
diagnosed, giving a crude incidence rate of 6 per 1,000 person-months. For all cases in the 
experimental group, the 20-months survival rate (no ONJ) was 100% compared to 87% in the 
control group (p>0.05) (See figure). 
 
  
CHAPTER 4 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
  
Antiresorptive agents that target osteoclasts, thereby inhibiting bone resorption and 
subsequent bone loss, currently are considered the cornerstone for the treatment and 
prevention of bone metastases of solid tumors [16, 17]. In the past, intravenous BPs (i.e. 
zoledronic acid) were considered the gold standard for the treatment of such conditions. Since 
2003, there has been an increase in number of case reports regarding ONJ induced by BPs, 
especially with intravenous administration. ONJ is described as adverse drug reaction described 
as the progressive destruction and death of bone that affects the mandible or maxilla of 
patients exposed to the treatment with nitrogen-containing bisphosphonates, in the absence of 
a previous radiation treatment. This an uncommon drug-related complication ranges from 
asymptomatic to requiring extensive operative treatment and adversely affecting patients’ 
qualify of life. 
Generally, the incidence of ONJ with intravenous bisphosphonates has been reported 0.8–1.2 % 
on average, increasing up to 21 % after injection of bisphosphonate for 3 years or more [43].  
In particular, in literature, among cancer patients exposed to zoledronate, the incidence of 
developing ONJ was, 0.5 at 1 year, 1,0 at 2 years, and 1.3 at 3 years [7].  
In our prospective study, the median period of observation with zoledronic acid and high-dose 
of vitamin D supplementation  was of 14,03 (SD=±2,77).  
About risk factors, it is well known that in solid cancer patients, such as breast cancer and 
prostate cancer, or in patients with multiple myeloma, the risk of ONJ is higher than in patients 
with other diseases [43-45].  In our sample, breast and prostate cancer were the two major 
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cancer involved the two group (T and C) of patients with 50,0% and 28,0% respectively. Other 
indications were multiple myeloma, lung, colon, liver. 
Regarding local risk factors, dentoalveolar surgery is considered one of the major risk factor for 
developing of ONJ; according to the literature, it is estimated that the incidence of the side 
effect after tooth extraction ranges from 1.6% to 14.8% of cases [46].  It is well known that the 
application of dental preventive measures before the initiation of the bisphosphonate therapy  
reduced the incidence of jaw osteonecrosis [47]. In fact, compared to retrospective studies on 
patients who did not receive dental examination before bisphosphonate administration, there 
are numerous prospective studies that show a decrease in ONJ when a dental examination is 
performed before treatment [23, 48, 49]. According to this, the population enrolled in our 
sample received an appropriate dental examination before antiresorptive assumption and 
thanks to our accurate preventive screening no dental extractions have been needed in any two 
groups until now. 
Nowadays, pre-existing inflammatory dental disease, such as periodontal disease or periapical 
pathology, is a well recognized risk factor [11]. In patients with cancer and ONJ, pre-existing 
inflammatory dental disease was a risk factor in 50% of cases [11, 23]. Given that a common 
treatment of inflammatory dental disease is tooth extraction, pre-existing dental disease may 
confound the relation between tooth extraction and the risk for ONJ noted earlier. To exclude 
periodontal disease, patients underwent an oral hygiene session every and not more than 6 
months after clinical evaluation and chlorexidine (0,2% mouthwashes 30 ml swished up to 60 
seconds, 3 times/ daily for 7 days) were prescribed. Data of each patient was collected and 
registered in a periodontal chart, evaluating plaque index, bleeding on probing (BoP), clinical 
attachment level (CAL) and tooth loss (TL). 
Regarding vitamin D levels and dental health, Ferrari HA Bischoff, showed that circulating levels 
of 25 (OH) D are strongly correlated with gingival health, dental care and the risk of developing 
periodontitis and gingivitis. Moreover, vitamin D may also reduce both gingivitis and 
periodontal disease through its antiinflammatory effect [50]. Thanks to close dental-
periodontal re-evaluation, patients showed good oral hygiene during follow up. In any case, no 
statistically significant differences were observed until now. 
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CONCLUSION 
The present study is the first prospective study investigating the role of high-dose vitamin D and 
evaluating the incidence of ONJ in a group of oncologic patients treated with zoledronic acid 
and high-dose vitamin D supplementation. 
Although many variables exist in ONJ pathogenesis, given the simplicity, safety and low costs of 
vitamin D supplementation, the potential protective effect on the development of ONJ may 
have important implications in clinical practice, making safer the administration of 
antiresorptive drugs.  
However, further investigation to assess the real benefit of high dose vitamin D 
supplementation in incidence of ONJ development in cancer patients treated with 
antiresorptive drugs are needed. 
 
  
CHAPTER 5 
 
 
 
 
 
Tables and Figures 
 
 
 
 
 
 
 
 
 
 
Tab 1. Group T: patients in primary prevention for antiresorptive-related ONJ receiving high dose 
vitamin D supplementation. 
 
 
 
ID Patient Ptazient Age (yrs) Gender Cancer Antiresorptive therapy Antiresorptive duration Systemic steroid therapy Other drug-related ONJ Local risk factors
1 TC 48 F Breast cancer Zoledronic acid 19 Yes No No
2 GB 68 M Lung cancer Zoledronic acid 13 No No No
3 AC 64 F Breast cancer Zoledronic acid 18 No No No
4 CS 54 M Prostate cancer Zoledronic acid 18 No No No
5 LS 52 F Breast cancer Zoledronic acid 17 No No No
6 FR 54 M Microcitoma Zoledronic acid 16 No No No
7 MP 79 M Multiple Myeloma Zoledronic acid 16 No No No
8 FL 69 F Colon cancer Zoledronic acid 12 No No No
9 FP 55 F Breast cancer Zoledronic acid 13 No Bevacizumab No
10 MC 65 M Prostate cancer Zoledronic acid 13 No No No
11 RN 81 M Prostate cancer Zoledronic acid 13 No No No
12 PDM 79 M Prostate cancer Zoledronic acid 16 No No No
13 DM 51 F Breast cancer Zoledronic acid 12 No No No
14 RF 72 M Prostate cancer Zoledronic acid 11 No No No
15 SC 73 M Prostate cancer Zoledronic acid 11 No No No
16 CP 69 M Prostate cancer Zoledronic acid 17 No No No
17 SM 64 F Breast cancer Zoledronic acid 16 No No No
18 VS 70 M Prostate cancer Zoledronic acid 10 No No No
19 GM 53 F Breast cancer Zoledronic acid 16 No No No
20 GP 70 F Breast cancer Zoledronic acid 16 No No No
21 FC 79 F Breast cancer Zoledronic acid 16 No No No
22 DDS 81 M Prostate cancer Zoledronic acid 16 No No No
23 BS 59 M Prostate cancer Zoledronic acid 16 No No No
24 SP 45 F Breast cancer Zoledronic acid 11 No No No
25 CB 55 F Breast cancer Zoledronic acid 12 No No No
26 RM 58 F Breast cancer Zoledronic acid 12 No No No
27 GS 67 F Multiple Myeloma Zoledronic acid 12 No No No
28 TV 75 M Prostate cancer Zoledronic acid 9 No No No
29 BG 80 M Prostate cancer Zoledronic acid 10 No No No
26 
 
 
 
Tab 2. Group C:  patients in primary prevention for antiresorptive-related ONJ without high dose vitamin D 
supplementation. 
 
 
 
Tab 3. ONJ clinical characteristics 
Legend 
ZDL: Zoledronic acid 
E/NE:  bon exposure / non exposure 
ID Patient Ptazient Age (yrs) Gender Cancer Antiresorptive therapy Antiresorptive duration Systemic steroid therapy Other drug-related ONJ Local risk factors
1 MA 36 F Multiple Myeloma Zoledronic acid 18 No No No
2 CA 55 F Breast cancer Zoledronic acid 24 No No No
3 PA 41 F Breast cancer Zoledronic acid 18 No No No
4 LB 63 F Breast cancer Zoledronic acid 11 No Bevacizumab No
5 TAB 60 M Multiple Myeloma Zoledronic acid 20 Yes No No
6 CB 46 M Colon cancer Zoledronic acid 25 Yes No No
7 PC 71 M Prostate cancer Zoledronic acid 14 No No No
8 BC 64 F Breast cancer Zoledronic acid 12 No No No
9 RC 47 F Breast cancer Zoledronic acid 17 No No No
10 GC 67 M Lung cancer Zoledronic acid 13 No No No
11 AC 32 F Breast cancer Zoledronic acid 12 No Bevacizumab No
12 CDG 78 M Prostate cancer Zoledronic acid 25 No No No
13 EF 62 F Breast cancer Zoledronic acid 13 No No No
14 GF 63 F Breast cancer Zoledronic acid 16 Yes No No
15 GF 68 M Lung cancer Zoledronic acid 15 No No No
16 GF 70 M Prostate cancer Zoledronic acid 14 No No No
17 PF 78 M Colon cancer Zoledronic acid 20 No No No
18 RG 67 F Breast cancer Zoledronic acid 15 No No No
19 ALB 76 F Multiple Myeloma Zoledronic acid 23 No No No
20 GLS 65 M Prostate cancer Zoledronic acid 25 No No No
21 SLN 81 M Lung cancer Zoledronic acid 15 No No No
22 CM 55 F Breast cancer Zoledronic acid 21 No No No
23 VM 58 F Breast cancer Zoledronic acid 16 No No No
24 SM 68 M Prostate cancer Zoledronic acid 14 No No No
25 MRM 56 F Breast cancer Zoledronic acid 26 No No No
26 MGM 60 F Breast cancer Zoledronic acid 8 No No No
27 AM 65 F Colon cancer Zoledronic acid 14 No Bevacizumab No
28 SM 67 F Breast cancer Zoledronic acid 24 No No No
29 MM 65 F Breast cancer Zoledronic acid 27 No No No
30 AP 71 F Breast cancer Zoledronic acid 12 No No No
31 PP 52 F Breast cancer Zoledronic acid 12 No Bevacizumab No
32 GP 43 F Breast cancer Zoledronic acid 10 No No No
33 FR 50 M Lung cancer Zoledronic acid 12 Yes No No
34 GS 75 M Prostate cancer Zoledronic acid 16 No No No
35 GS 49 F Breast cancer Zoledronic acid 15 No No No
36 MS 45 F Breast cancer Zoledronic acid 25 No No No
37 CS 51 M Prostate cancer Zoledronic acid 18 No No No
38 VS 65 F Multiple Myeloma Zoledronic acid 12 No No No
39 AMT 50 F Breast cancer Zoledronic acid 17 No No No
40 AT 44 F Breast cancer Zoledronic acid 21 No No No
41 GV 50 F Breast cancer Zoledronic acid 27 Yes No No
42 EZ 45 F Breast cancer Zoledronic acid 12 No No No
43 MA 69 F Breast cancer Zoledronic acid 29 No No No
44 FPB 63 M Prostate cancer Zoledronic acid 16 No No No
45 MC 66 M Multiple Myeloma Zoledronic acid 34 No No No
46 MDB 55 F Breast cancer Zoledronic acid 34 No No No
47 MGN 62 F Breast cancer Zoledronic acid 23 No No No
48 GP 72 M Prostate cancer Zoledronic acid 24 No No No
49 SE 68 M Liver cancer Zoledronic acid 2 No No No
50 AG 60 F Breast cancer Zoledronic acid 17 No No No
51 FF 43 M Prostate cancer Zoledronic acid 7 No No No
52 RC 72 M Prostate cancer Zoledronic acid 12 No No No
53 RDS 58 F Breast cancer Zoledronic acid 17 No No No
ID Patient Ptazient Cancer ONJ localization ZLD duration (months) Clinical sign (E/NE) Abscess Pain SICMF-SIPMO Stadiation
48 GP Prostate cancer Mandibular 24 E No No 2
49 SE Liver cancer Mandibular 2 E No No 1
50 AG Breast cancer Mandibular 17 E No Yes 1
51 FF Prostate cancer Mandibular 7 E Yes No 2
52 RC Prostate cancer Mandibular 12 NE Yes No 1
53 RDS Breast cancer Mandibular 17 E No No 1
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Tab 3. Survival analysis 
 
 
 Survival rates 
Months Control group Experimental group 
3 98.0 100.0 
6 98.0 100.0 
12 94.0 100.0 
18 87.0 100.0 
24 81.0 100.0 
 
Tab 4. Incidence rates
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